Business
COEGIN: Follicopeptide targets a Q4 2025 launch in Europe and the U.S., with strong clinical results and partner support
COEGIN: Follicopeptide targets a Q4 2025 launch in Europe and the U.S., with strong clinical results and partner support
About this update from Coegin Pharma Ab
Follicopeptide, a novel hair growth peptide, is set for a Q4 2025 launch in Europe and the U.S., with production and regulatory processes on schedule. Clinical studies show over 70% efficacy, and commercialization will occur through established partners.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.